Novavax to produce Canadian supply of COVID-19 vaccine in Canada

By The Science Advisory Board staff writers

February 2, 2021 -- Novavax has signed a memorandum of understanding with the Canadian government to produce the company's protein-based COVID-19 vaccine candidate, NVX-CoV2373, in Canada.

Novavax plans to produce NVX-CoV2373 at the National Research Council's Biologics Manufacturing Centre in Montreal after the candidate and the facility receive approval by Health Canada. The government previously agreed to purchase up to 76 million doses of NVX-CoV2373, which is undergoing rolling submission for regulatory approval by Health Canada.

The memorandum also includes the broader intention for the Canadian government and Novavax to work together to increase the company's presence in Canada. Together, they will explore partnership opportunities for Novavax to expand vaccine production in Canada, including utilizing Canadian contract manufacturers.

"Pursuing domestic manufacturing of Novavax' COVID-19 vaccine at the National Research Council's Royalmount facility is part of our government's commitment to protect the health and safety of all Canadians today, and in the future," said François-Philippe Champagne, the minister of innovation, science and industry in Canada.

Novavax COVID-19 vaccine phase III trial indicates up to 89% efficacy
Novavax announced that its protein-based COVID-19 vaccine candidate, NVX-CoV2373, met the primary end point in a U.K. phase III clinical trial, achieving...
Canada ups COVID-19 vaccine order from Novavax to 76M doses
Novavax has finalized an agreement with the Canadian government to supply up to 76 million doses of NVX-CoV2373, a recombinant protein-based COVID-19...
New Zealand to purchase 10.7M doses of Novavax COVID-19 vaccine
The government of New Zealand has agreed to purchase 10.7 million doses of Novavax's COVID-19 vaccine candidate, NVX-CoV2373.
Novavax provides updates on COVID-19 vaccine
Novavax has reported that it is making "meaningful progress" on its COVID-19 vaccine, NVX‑CoV2373.

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter